An interventional study of Intracardiac Echocardiography (ICE) in Atrial Fibrillation and Left Atrial Appendage Thrombosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Atrial Fibrillation by The Cleveland Clinic — 10 open to participants now, 11 under way, 1 of them phase 3. Atrial Fibrillation · The Cleveland Clinic.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 18th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →10 of the 26 studies in Atrial Fibrillation by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18–85
The Cleveland Clinic · Sites in United States
Ages 22+
The Cleveland Clinic · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 90 across the 13 interventional studies, 60 across the 13 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
4 of the studies in Atrial Fibrillation by The Cleveland Clinic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07893275Phase 3The Cleveland ClinicSGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial | 2027-10 |
| NCT07087587The Cleveland ClinicSleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA): | 2026-12-31 |
| NCT06802081The Cleveland ClinicTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | 2026-12-31 |
| NCT07083115The Cleveland ClinicDeveloping MRI Technologies for Atrial Fibrillation | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Atrial Fibrillation by The Cleveland Clinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.
Left atrial appendage occlusion is approved as an indicated therapy for patients with non valvular atrial fibrillation, high risk of stroke and an appropriate rationale for avoidance of long term use of oral anticoagulants.
Concurrent procedural TEE is an integral part of the procedure. It is used to guide trans-septal puncture, device sizing and assessment of final adequacy of device implant.
TEE requires the participation and guidance of a cardiac imager and because the TEE probe is in place for a relatively long duration the procedure, the procedure is most commonly performed under general anesthesia. Furthermore TEE can be associated with risk of injury to the oropharynx and esophagus. Our ongoing clinical experience and known literature suggest that TEE may not be necessary for the overall success of the procedure. The objective of the study is to investigate a new work flow that may ultimately demonstrate that intra-procedural TEE may not be necessary, obviating the need for additional personnel, general anesthesia and decreasing overall risk. ICE has been widely used to aid trans-septal puncture and visualize left atrial anatomy. Smaller studies and case series have reported the use of ICE as an alternative to TEE in guiding Watchman device implant. This has not been compared systematically with TEE in a large patient sample.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intracardiac Echocardiography (ICE)
Device: Intracardiac Echocardiography (ICE)
ICE will be used to guide trans-septal puncture and to guide device implant.
Successful Watchman implantation using intracardiac echocardiography (ICE) guidance
Intracardiac echocardiography (ICE) guided Watchman placement confirmed by transesophageal echocardiography (TEE)
Time frame: During the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 60 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.